Success Metrics

Clinical Success Rate
95.3%

Based on 41 completed trials

Completion Rate
95%(41/43)
Active Trials
3(6%)
Results Posted
24%(10 trials)
Terminated
2(4%)

Phase Distribution

Ph early_phase_1
1
2%
Ph not_applicable
5
10%
Ph phase_1
3
6%
Ph phase_4
14
28%
Ph phase_2
11
22%
Ph phase_3
12
24%

Phase Distribution

4

Early Stage

11

Mid Stage

26

Late Stage

Phase Distribution46 total trials
Early Phase 1First-in-human
1(2.2%)
Phase 1Safety & dosage
3(6.5%)
Phase 2Efficacy & side effects
11(23.9%)
Phase 3Large-scale testing
12(26.1%)
Phase 4Post-market surveillance
14(30.4%)
N/ANon-phased studies
5(10.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

95.3%

41 of 43 finished

Non-Completion Rate

4.7%

2 ended early

Currently Active

3

trials recruiting

Total Trials

50

all time

Status Distribution
Active(4)
Completed(41)
Terminated(2)
Other(3)

Detailed Status

Completed41
unknown3
Recruiting2
Terminated2
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
50
Active
3
Success Rate
95.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (2.2%)
Phase 13 (6.5%)
Phase 211 (23.9%)
Phase 312 (26.1%)
Phase 414 (30.4%)
N/A5 (10.9%)

Trials by Status

unknown36%
active_not_recruiting12%
not_yet_recruiting12%
recruiting24%
completed4182%
terminated24%

Recent Activity

Clinical Trials (50)

Showing 20 of 50 trialsScroll for more
NCT06944145Phase 2

New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia

Recruiting
NCT07470606Phase 2

Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain

Not Yet Recruiting
NCT06055179Not Applicable

XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)

Recruiting
NCT00427700Phase 3

Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome

Completed
NCT04926545Not Applicable

XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study)

Completed
NCT01573637Phase 3

Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women

Completed
NCT01416194

Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)

Completed
NCT05172050Phase 2

Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.

Completed
NCT04736693

Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data

Completed
NCT03623633Phase 4

Comparative Antiresorptive Efficacy Discontinuation of Denosumab

Active Not Recruiting
NCT01077817

Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)

Completed
NCT03043820Phase 3

Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder

Completed
NCT03006003Phase 4

Osteoporosis Treatment in Post-menopausal Women

Unknown
NCT01607320Not Applicable

Efficacy Study of Raloxifene to Induce Ovulation in Polycystic Ovarian Syndrome

Terminated
NCT00687102Phase 3

Cognition in the Study of Tamoxifen and Raloxifene

Completed
NCT03010267Phase 1

DP-R213 Phase 1 Pharmacokinetics Study

Completed
NCT01050842Early Phase 1

Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer

Completed
NCT02977949

The Effects of Seasonal Changes in Osteoporosis Treatment

Unknown
NCT02762643Phase 1

DP-R213 Pharmacokinetics Study

Completed
NCT00001848Phase 2

The Safety and Effectiveness of Surgery With or Without Raloxifene for the Treatment of Pelvic Pain Caused by Endometriosis

Completed

Drug Details

Intervention Type
DRUG
Total Trials
50